Pub Date : 2020-04-01DOI: 10.1177/0300891620914150
N. Tolba, AS Alsedfy, SW Skandar, Y. El-kerm
Introduction: Triple negative breast cancer (TNBC) is defined by the absence of ER expression, PR expression and HER2 amplification. No targeted treatment is available for TNBC and chemotherapy remains the best therapeutic option. However, in the case of recurrence or chemo-resistance, therapeutic options are very limited. TNBC presents a high rate of proliferation and is highly aggressive having low survival rate. As the complexity of this disease is being simplified over time, new targets are also being discovered for the treatment of this disease. Therefore, there is still need for new biomarkers, which would serve for targeted treatment. Transgelin was proposed as a new potential cancer biomarker. Altered expression of Transgelin has been described in a wide range of cancers, often with contradictory results. The aim of the study was to compare Transgelin expression across molecular subtypes of breast cancer, to identify if it can be used as a future molecular targeted protein for TNBC. Material and Methods: Transgelin immunohistochemistry was applied on 60 retrospectively collected paraffin blocks of patients presenting with invasive breast carcinoma (NST) having different molecular subtypes. Blocks were collected between 2015 and 2016 from Pathology department, Medical Research Institute, Egypt. Her2 equivocal cases were excluded from the study. Results: Transgelin expression was positive in 23 cases and negative in 37 cases. There was a statistically significant difference between (Transgelin +) and (Transgelin -) cases being highly expressed in TNBC in comparison to other molecular subtypes. It was also highly expressed in tumors with large size, high grade, positive lymph-vascular invasion status & lymph node metastasis. There was no statistically significant difference between (Transgelin+) and (Transgelin-) as regards age and Her2 status. Conclusions: Transgelin is an aggressive biomarker differentially expressed among the molecular breast cancer subtypes with high expression in TNBC. Transgelin may provide a potential target for future treatment of TNBC.
简介:三阴性乳腺癌(Triple negative breast cancer, TNBC)的定义是缺乏ER表达、PR表达和HER2扩增。目前尚无针对TNBC的靶向治疗方法，化疗仍然是最佳的治疗选择。然而，在复发或化疗耐药的情况下，治疗选择非常有限。TNBC具有高增殖率和高侵袭性，生存率低。随着时间的推移，这种疾病的复杂性正在被简化，治疗这种疾病的新靶点也正在被发现。因此，仍然需要新的生物标志物，以服务于靶向治疗。Transgelin被认为是一种新的潜在的癌症生物标志物。Transgelin表达的改变已经在许多癌症中被描述，通常有相互矛盾的结果。该研究的目的是比较Transgelin在乳腺癌分子亚型中的表达，以确定它是否可以用作TNBC的未来分子靶向蛋白。材料与方法:回顾性采集60例不同分子亚型浸润性乳腺癌患者石蜡切片，应用Transgelin免疫组化技术。样本于2015年至2016年从埃及医学研究所病理学系收集。Her2例模棱两可的病例被排除在研究之外。结果:Transgelin阳性23例，阴性37例。与其他分子亚型相比，TNBC中高表达的(Transgelin +)和(Transgelin -)病例之间存在统计学差异。它在大体积、高分级、淋巴血管侵袭阳性及淋巴结转移的肿瘤中也高表达。(Transgelin+)和(Transgelin-)在年龄和Her2状态方面无统计学差异。结论:Transgelin是一种具有侵袭性的生物标志物，在TNBC中高表达，在不同的乳腺癌分子亚型中有差异表达。Transgelin可能为未来治疗TNBC提供一个潜在的靶点。
{"title":"Expression of Transgelin in Triple Negative and Non Triple Negative Breast Cancer: A Differential Study","authors":"N. Tolba, AS Alsedfy, SW Skandar, Y. El-kerm","doi":"10.1177/0300891620914150","DOIUrl":"https://doi.org/10.1177/0300891620914150","url":null,"abstract":"Introduction: Triple negative breast cancer (TNBC) is defined by the absence of ER expression, PR expression and HER2 amplification. No targeted treatment is available for TNBC and chemotherapy remains the best therapeutic option. However, in the case of recurrence or chemo-resistance, therapeutic options are very limited. TNBC presents a high rate of proliferation and is highly aggressive having low survival rate. As the complexity of this disease is being simplified over time, new targets are also being discovered for the treatment of this disease. Therefore, there is still need for new biomarkers, which would serve for targeted treatment. Transgelin was proposed as a new potential cancer biomarker. Altered expression of Transgelin has been described in a wide range of cancers, often with contradictory results. The aim of the study was to compare Transgelin expression across molecular subtypes of breast cancer, to identify if it can be used as a future molecular targeted protein for TNBC. Material and Methods: Transgelin immunohistochemistry was applied on 60 retrospectively collected paraffin blocks of patients presenting with invasive breast carcinoma (NST) having different molecular subtypes. Blocks were collected between 2015 and 2016 from Pathology department, Medical Research Institute, Egypt. Her2 equivocal cases were excluded from the study. Results: Transgelin expression was positive in 23 cases and negative in 37 cases. There was a statistically significant difference between (Transgelin +) and (Transgelin -) cases being highly expressed in TNBC in comparison to other molecular subtypes. It was also highly expressed in tumors with large size, high grade, positive lymph-vascular invasion status & lymph node metastasis. There was no statistically significant difference between (Transgelin+) and (Transgelin-) as regards age and Her2 status. Conclusions: Transgelin is an aggressive biomarker differentially expressed among the molecular breast cancer subtypes with high expression in TNBC. Transgelin may provide a potential target for future treatment of TNBC.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"68 6 1","pages":"20 - 20"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76494784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891620914152
N. Talibova, A. Sohaib, M. Gouda, M. Gunaldı
Intoduction: Gynecological malignancies are one of the most common cancers in women and have high mortality rates in the United States. In this study, we aimed to analyze the incidence and mortality rates of gynecological malignancies in 2011-2015 and compare these data with the corresponding parameters of 2001-2005. We chose these intervals of years for contrasting, as HPV vaccines have been actively used since 2006. HPV vaccine is known to prevent cervical cancer but has unknown impact on other gynecological malignancies. The aim of the is study is to check if incidence and survival of gynecological malignancies has changed before and after application of HPV vaccine Material and Methods: The Surveillance, Epidemiology and End Results (SEER) cancer registry 2005-2011 and 2011-2015 database was investigated and patients with gynecological malignancy were identified. Data were obtained using SEER*Stat version 8.3.5. A statistical analysis on the incidence rate and mortality rate was performed. Data were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25. Results: Overall 125,357 cases with a gynecological malignancy were identified in 2011-2015 in comparison with 102,534 cases in the period of 2001-2005. The incidence of cervical cancer decreased in the period of 2011-2015 compared with the period from 2001 to 2005 (median incidence rates 3.9 and 4.3 per 100.000 persons, respectively, p < 0.05), while incidence of uterine (15.3 and 12.0 per 100.000 persons persons, respectively) and vulvar (1.55 and 1.86 per 100.000 persons, respectively) has increased (p < 0.05). There was no change in the incidence rate of ovarian cancer (7.28 and 7.19 per 100.000 persons). Survival rates for cervix, uterine, ovarian and vulva cancer have increased. However, zero time error couldn’t be avoided in statistical analysis. Conclusion: As a result of widespread screening with Pap smear test and availability of human papilloma virus vaccine the incidence of cervix cancer has declined. Increase in vulvar and uterine cancer incidence may be attributed to lack of effective screening program for early detection of these type of cancers and most probably HPV vaccine has no effect on their incidence. Survival of gynecological malignancies has increased over years which may be explained by better treatment options or earlier detection.
{"title":"Incidence and Survival Rates of Gynecological Malignancies in The United States Before and After the HPV Vaccine","authors":"N. Talibova, A. Sohaib, M. Gouda, M. Gunaldı","doi":"10.1177/0300891620914152","DOIUrl":"https://doi.org/10.1177/0300891620914152","url":null,"abstract":"Intoduction: Gynecological malignancies are one of the most common cancers in women and have high mortality rates in the United States. In this study, we aimed to analyze the incidence and mortality rates of gynecological malignancies in 2011-2015 and compare these data with the corresponding parameters of 2001-2005. We chose these intervals of years for contrasting, as HPV vaccines have been actively used since 2006. HPV vaccine is known to prevent cervical cancer but has unknown impact on other gynecological malignancies. The aim of the is study is to check if incidence and survival of gynecological malignancies has changed before and after application of HPV vaccine Material and Methods: The Surveillance, Epidemiology and End Results (SEER) cancer registry 2005-2011 and 2011-2015 database was investigated and patients with gynecological malignancy were identified. Data were obtained using SEER*Stat version 8.3.5. A statistical analysis on the incidence rate and mortality rate was performed. Data were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25. Results: Overall 125,357 cases with a gynecological malignancy were identified in 2011-2015 in comparison with 102,534 cases in the period of 2001-2005. The incidence of cervical cancer decreased in the period of 2011-2015 compared with the period from 2001 to 2005 (median incidence rates 3.9 and 4.3 per 100.000 persons, respectively, p < 0.05), while incidence of uterine (15.3 and 12.0 per 100.000 persons persons, respectively) and vulvar (1.55 and 1.86 per 100.000 persons, respectively) has increased (p < 0.05). There was no change in the incidence rate of ovarian cancer (7.28 and 7.19 per 100.000 persons). Survival rates for cervix, uterine, ovarian and vulva cancer have increased. However, zero time error couldn’t be avoided in statistical analysis. Conclusion: As a result of widespread screening with Pap smear test and availability of human papilloma virus vaccine the incidence of cervix cancer has declined. Increase in vulvar and uterine cancer incidence may be attributed to lack of effective screening program for early detection of these type of cancers and most probably HPV vaccine has no effect on their incidence. Survival of gynecological malignancies has increased over years which may be explained by better treatment options or earlier detection.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"9 1","pages":"22 - 22"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87269695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891620914151
N. A. Abdel Aziz, G. Elgohary, S. Khallaf, S. Mohamed, W. Abozeed, O. Nabeeh, M. Alhawary, S. Khalid, A. Abdel Warith
Background: Emotional distress is common among cancer patients (25-30 %), as a result of the serious diagnosis and suffering from aggressive treatment. This may negatively affect their participation in treatment, quality of life, and satisfaction with care. To best of our knowledge, it has not been studied before in Egypt, this study aims to implement the distress thermometer in Egyptian cancer patients as a screening tool for the distress and its associated factors. Methods: The Arabic version of DT that has been recently validated was used in this study to screen patients. Egyptian Patients diagnosed with different types of hematological malignancies and solid cancers who were following at three Oncology Centers (South Egypt Cancer Institute, Assiut University Hospital, and Mansura University Oncology department) were recruited. All Patients were asked to rate their distress in the past week on an 11-point visual analog scale ranging from 0 (no distress) to 10 (extreme distress), then, they were asked to fill in the Problem List (PL), to check whether or not they had any of the problems listed during the previous 7 days. Univariate and multivariate analyses were used to identify the significant problems correlated with the patient distress at a cut-off score of 4. Results: A total of 550 patients agreed to participate. The mean age was 51.3 (18–85) years. Different types of solid and hematological malignancies were included; the most common three types were breast cancer (32.7 %), gastrointestinal cancer (23%), and hematological malignancies (15.5 %). The patients’ average DT score was 3.7. The most frequent problems were fatigue (49%), worry (47%), fear (44 %), and pain (42%). The univariate analysis showed a significant correlation between the DT at Cut – off the value of 4 and transportation, dealing with children, depression, fears, sadness, sleep, loss of usual activity, and fatigue. Multivariate analysis confirmed the transportation, depression, fears, sadness, sleep and fatigue as independent factors for such distress. Conclusion: Egyptian cancer patients are suffering from significant distress at a cut value of 4. We recommend the involvement of the psycho-oncology service for all cancer patients at the time of diagnosis.
{"title":"Is it the Time to Implement the Routine Use of Distress Thermometer Among Egyptian Cancer Patients?","authors":"N. A. Abdel Aziz, G. Elgohary, S. Khallaf, S. Mohamed, W. Abozeed, O. Nabeeh, M. Alhawary, S. Khalid, A. Abdel Warith","doi":"10.1177/0300891620914151","DOIUrl":"https://doi.org/10.1177/0300891620914151","url":null,"abstract":"Background: Emotional distress is common among cancer patients (25-30 %), as a result of the serious diagnosis and suffering from aggressive treatment. This may negatively affect their participation in treatment, quality of life, and satisfaction with care. To best of our knowledge, it has not been studied before in Egypt, this study aims to implement the distress thermometer in Egyptian cancer patients as a screening tool for the distress and its associated factors. Methods: The Arabic version of DT that has been recently validated was used in this study to screen patients. Egyptian Patients diagnosed with different types of hematological malignancies and solid cancers who were following at three Oncology Centers (South Egypt Cancer Institute, Assiut University Hospital, and Mansura University Oncology department) were recruited. All Patients were asked to rate their distress in the past week on an 11-point visual analog scale ranging from 0 (no distress) to 10 (extreme distress), then, they were asked to fill in the Problem List (PL), to check whether or not they had any of the problems listed during the previous 7 days. Univariate and multivariate analyses were used to identify the significant problems correlated with the patient distress at a cut-off score of 4. Results: A total of 550 patients agreed to participate. The mean age was 51.3 (18–85) years. Different types of solid and hematological malignancies were included; the most common three types were breast cancer (32.7 %), gastrointestinal cancer (23%), and hematological malignancies (15.5 %). The patients’ average DT score was 3.7. The most frequent problems were fatigue (49%), worry (47%), fear (44 %), and pain (42%). The univariate analysis showed a significant correlation between the DT at Cut – off the value of 4 and transportation, dealing with children, depression, fears, sadness, sleep, loss of usual activity, and fatigue. Multivariate analysis confirmed the transportation, depression, fears, sadness, sleep and fatigue as independent factors for such distress. Conclusion: Egyptian cancer patients are suffering from significant distress at a cut value of 4. We recommend the involvement of the psycho-oncology service for all cancer patients at the time of diagnosis.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"9 1","pages":"21 - 21"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86676782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891620914158
M. Hammad, MS Alwaraky, MA Maaly, Mary A. Kamel, H. Hamza
Introduction: Abnormal uterine bleeding is one of the most frequent gynecological and obstetrics problems. Till the recent decades, myomectomy and hysterectomy were the only treatment options available to control uterine bleeding regardless the morbidity and mortality. Over the past decade, uterine artery embolization (UAE) has become a popular alternative treatment. Our study aim is to evaluate the efficacy of UAE for the treatment of uterine bleeding of different etiologies as Fibroids & uterine arterio-venous malformation (AVM). Material & Methods: Thirty patients were enrolled in the study: 28 patients with fibroids & 2 patients with AVM, all underwent UAE by PVA for fibroid & Hystroacryl with lipidol & coils for AVM. Bleeding as an end point was Followed up for 6 months. Results: Cessation of bleeding with no recurrence through the 6 months of follow up. UAE significantly decreased the bleeding towels from 4.4 to 2 towels after 6 months. As well, the menstrual duration was reduced from 7.6 to 4.4 days (p < 0.05*). Hemoglobin level was boosted from 10.7 to 11.4 gm/dl after 6 months (p=0.001*). As well, the fibroid size was significantly reduced from 314.7 to 70.4 cm3 after 6 months (p < 0.05*). The AVM cases have completely recovered & one of them got pregnant with delivery of normal fetus with no reported complication. The majority of our patients showed high level of satisfaction with the obtained outcomes. Conclusion: UAE, either unilateral or bilateral, is a safe and effective technique for management of abnormal uterine bleeding of fibroids & AVM origin. A high clinical success rate and fibroid volume with the mean menstrual duration& amount reduction can be achieved.
{"title":"Role of Uterine Artery Embolization in Management of Uterine Lesions with Abnormal Uterine Bleeding","authors":"M. Hammad, MS Alwaraky, MA Maaly, Mary A. Kamel, H. Hamza","doi":"10.1177/0300891620914158","DOIUrl":"https://doi.org/10.1177/0300891620914158","url":null,"abstract":"Introduction: Abnormal uterine bleeding is one of the most frequent gynecological and obstetrics problems. Till the recent decades, myomectomy and hysterectomy were the only treatment options available to control uterine bleeding regardless the morbidity and mortality. Over the past decade, uterine artery embolization (UAE) has become a popular alternative treatment. Our study aim is to evaluate the efficacy of UAE for the treatment of uterine bleeding of different etiologies as Fibroids & uterine arterio-venous malformation (AVM). Material & Methods: Thirty patients were enrolled in the study: 28 patients with fibroids & 2 patients with AVM, all underwent UAE by PVA for fibroid & Hystroacryl with lipidol & coils for AVM. Bleeding as an end point was Followed up for 6 months. Results: Cessation of bleeding with no recurrence through the 6 months of follow up. UAE significantly decreased the bleeding towels from 4.4 to 2 towels after 6 months. As well, the menstrual duration was reduced from 7.6 to 4.4 days (p < 0.05*). Hemoglobin level was boosted from 10.7 to 11.4 gm/dl after 6 months (p=0.001*). As well, the fibroid size was significantly reduced from 314.7 to 70.4 cm3 after 6 months (p < 0.05*). The AVM cases have completely recovered & one of them got pregnant with delivery of normal fetus with no reported complication. The majority of our patients showed high level of satisfaction with the obtained outcomes. Conclusion: UAE, either unilateral or bilateral, is a safe and effective technique for management of abnormal uterine bleeding of fibroids & AVM origin. A high clinical success rate and fibroid volume with the mean menstrual duration& amount reduction can be achieved.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"46 1","pages":"27 - 27"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86703013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891620914176
Mohammed Gamil, M. Murad, Nelly Hassan Ali el din, A. Zakaria
Background: The frequency of mesenchymal breast tumors is very low, being represented mostly by tumors with biphasic proliferation (phyllodes tumors) and less by other types of non-epithelial tumors. Objective: To review the Management of phyllodes tumors of the breast in the NCI Cairo university during a period of 10 years (2000 till 2010). Material and Methods: Retrospective study including 99 patients who diagnosed and treated with phyllodes tumors of the breast between (2000 to 2010). Data were collected from the biostatistics and cancer epidemiology department. Results: Out of 99 patients; 51 (51.5%) were benign and 32 (32.3%) were borderline and 16 (16%) were malignant; the median age of the study population was 45.5 years (range 18–71 years).The main radiological tool of diagnosis was breast US and mammography 100%. Preoperative fine needle aspiration (FNA) was performed in 12(37.5%) cases for cytodiagnosis but true cut biopsy was done in 87 (87%) cases. Wide local excision was done in 86%, wide local excision with axillary evacuation was done in 1% only, simple mastectomy was done in 9.3% and modified radical mastectomy was done only in 3% of all cases. Conclusion: Different surgical modalities are considered the main line for management of phyllodes breast tumors. Local recurrence can be avoided with wide local excision from the first surgery. Axillary LN dissection is not a role in management of breast PT.
{"title":"Fibroepithelial Breast Tumors: Cohort Study","authors":"Mohammed Gamil, M. Murad, Nelly Hassan Ali el din, A. Zakaria","doi":"10.1177/0300891620914176","DOIUrl":"https://doi.org/10.1177/0300891620914176","url":null,"abstract":"Background: The frequency of mesenchymal breast tumors is very low, being represented mostly by tumors with biphasic proliferation (phyllodes tumors) and less by other types of non-epithelial tumors. Objective: To review the Management of phyllodes tumors of the breast in the NCI Cairo university during a period of 10 years (2000 till 2010). Material and Methods: Retrospective study including 99 patients who diagnosed and treated with phyllodes tumors of the breast between (2000 to 2010). Data were collected from the biostatistics and cancer epidemiology department. Results: Out of 99 patients; 51 (51.5%) were benign and 32 (32.3%) were borderline and 16 (16%) were malignant; the median age of the study population was 45.5 years (range 18–71 years).The main radiological tool of diagnosis was breast US and mammography 100%. Preoperative fine needle aspiration (FNA) was performed in 12(37.5%) cases for cytodiagnosis but true cut biopsy was done in 87 (87%) cases. Wide local excision was done in 86%, wide local excision with axillary evacuation was done in 1% only, simple mastectomy was done in 9.3% and modified radical mastectomy was done only in 3% of all cases. Conclusion: Different surgical modalities are considered the main line for management of phyllodes breast tumors. Local recurrence can be avoided with wide local excision from the first surgery. Axillary LN dissection is not a role in management of breast PT.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"26 1","pages":"39 - 39"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77127740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891620914134
Samah A. Loutfy, S. Metwally, M. Abo-Shadi, NF Abdel Fattah, A. Osman, MM Moneer, A. Helal
Presenting Author: Loutfy SA Introduction: Oncogenic viruses including Mouse Mammary Tumor Virus (MMTV), Adenovirus (ADV), Polyomavirus (PoV), Human Papillomavirus (HPV), and Epstein–Barr virus (EBV) are one of the leading probable direct causes of Breast cancer (BC) worldwide. According to the National population-based registry program in Egypt (2008-2011) accounting for 32% of all female cancers. The present study aimed at evaluating the presence of these five oncogenic viruses among Egyptian familial and non-familial BC patients and their impact on the clinical course of the disease. Patients & Methods: The current study was conducted on 20 cases of BC patients without treatment and 10 healthy women as a control, aged between 18-45 years. Fresh frozen tissue and blood were obtained from BC patients, whereas only blood was obtained from control. All samples were subjected to qualitative and quantitative PCR assays to measure viral loads. The results were correlated to the clinicopathological parameters of breast cancer disease. Results: MMTV, ADV, PoV, HPV and EBV DNAs have been detected in 11 (55%),13 (65 %),8 (40%), 0 (0%) and 0 (0%) respectively, of 20 blood BC patients using qualitative PCR. PCR assay. Upon screening of 13 fresh frozen tissues, MMTV, ADV, PoV, HPV and EBV DNAs were present in 12(92%), 12(92%), 2(15.3%), 11(84.6%), and 11 (84.6) respectively of BC patients using quantitative PCR assay. Regarding viral load, ADV and HPV DNAs appeared to be the most replicative viruses out of all tested oncogenic viruses where their load ranged between 40 and 130,000 copies/ml. None of the tested viruses was detected in the control group. The presence of DNA of the 5 tested viruses was not associated with any clinicopathological parameters except larger tumor size was more common among BC patients with positive MMTV results. Conclusion: MMTV and ADV were the most common viruses present in tissue and blood of BC patients, tissue specimens are better for viral detection especially for EBV and papillomaviruses. The presence of oncogenic viral infection among young BC females could be considered as one of the risk external factor and could affect the path of BC disease and its prognosis.
{"title":"Presence of Oncogenic Viruses: Clinical Relevance Among Egyptian Familial and Non-Familial Breast Cancer","authors":"Samah A. Loutfy, S. Metwally, M. Abo-Shadi, NF Abdel Fattah, A. Osman, MM Moneer, A. Helal","doi":"10.1177/0300891620914134","DOIUrl":"https://doi.org/10.1177/0300891620914134","url":null,"abstract":"Presenting Author: Loutfy SA Introduction: Oncogenic viruses including Mouse Mammary Tumor Virus (MMTV), Adenovirus (ADV), Polyomavirus (PoV), Human Papillomavirus (HPV), and Epstein–Barr virus (EBV) are one of the leading probable direct causes of Breast cancer (BC) worldwide. According to the National population-based registry program in Egypt (2008-2011) accounting for 32% of all female cancers. The present study aimed at evaluating the presence of these five oncogenic viruses among Egyptian familial and non-familial BC patients and their impact on the clinical course of the disease. Patients & Methods: The current study was conducted on 20 cases of BC patients without treatment and 10 healthy women as a control, aged between 18-45 years. Fresh frozen tissue and blood were obtained from BC patients, whereas only blood was obtained from control. All samples were subjected to qualitative and quantitative PCR assays to measure viral loads. The results were correlated to the clinicopathological parameters of breast cancer disease. Results: MMTV, ADV, PoV, HPV and EBV DNAs have been detected in 11 (55%),13 (65 %),8 (40%), 0 (0%) and 0 (0%) respectively, of 20 blood BC patients using qualitative PCR. PCR assay. Upon screening of 13 fresh frozen tissues, MMTV, ADV, PoV, HPV and EBV DNAs were present in 12(92%), 12(92%), 2(15.3%), 11(84.6%), and 11 (84.6) respectively of BC patients using quantitative PCR assay. Regarding viral load, ADV and HPV DNAs appeared to be the most replicative viruses out of all tested oncogenic viruses where their load ranged between 40 and 130,000 copies/ml. None of the tested viruses was detected in the control group. The presence of DNA of the 5 tested viruses was not associated with any clinicopathological parameters except larger tumor size was more common among BC patients with positive MMTV results. Conclusion: MMTV and ADV were the most common viruses present in tissue and blood of BC patients, tissue specimens are better for viral detection especially for EBV and papillomaviruses. The presence of oncogenic viral infection among young BC females could be considered as one of the risk external factor and could affect the path of BC disease and its prognosis.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"59 1","pages":"14 - 14"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88254240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891620914131
S. Abdelhamid, H. El-mesallamy, Hm AbdelAziz, A. Zekri
Introduction: Germline mutations in BRCA1 and BRCA2 genes confer high risk of developing breast cancer. We sought to examine whether the clinicopathological characteristics and the clinical outcome differ in patients with and without BRCA mutations. Patients and Methods: A series of 103 Egyptian female patients were recruited from Breast Cancer Unit, Clinical Oncology Department, Ain Shams University, Egypt. The enrolled patients, unselected for age of onset or family history, were tested for BRCA1/2 mutations using HRM analysis and direct sequencing. The clinical and pathological features of the patients were retrospectively assessed and comparisons were made using Chi-square. Disease free survival (DFS) was estimated by Kaplan–Meier method and compared in the two groups with log-rank. Results: The overall rate of BRCA1/2 mutations was 44%. Novel deleterious mutations were detected and submitted to NCBI Clinvar database. Deleterious mutations were identified in 29 cases and unclassified variants in 32 cases, 15 of which had a co-occuring deleterious mutation. Patients with BRCA mutations tended to have early onset breast cancer compared to non-carriers (P=0.002), more often premenopausal (P=0.006), with a familial history of breast cancer as well as other cancers (P=0.005). BRCA-related breast cancers were more likely to have T3-T4 stage than wild type (41% versus 28%, P=0.02), positive lymph node involvement (78 versus 53%, P=0.007) and develop bilateral breast cancers (24% versus 9%, P =0.007). The incidence of ER negative and PR negative tumors was higher in BRCA carriers, but not statistically significant (P=0.17 and 0.15, respectively). No difference in HER-2/neu status was observed (P=0.25). Early age at onset, positive lymph node involvement, family history of any cancer were independent predictive factors for occurrence of BRCA1/2 mutations. The median follow-up time for the cohort was 5.53 years. Patients with BRCA mutations had poorer 5-year DFS compared to non-carriers (47.7% versus 67.4%, P=0.041); but Cox regression analysis failed to demonstrate a significant independent influence of BRCA mutation status on DFS. Conclusion: This study shows that BRCA-related breast cancers in the Egyptian population have distinctive clinical and tumor features as well as outcome. This data has important health implications for guiding cancer control policies.
{"title":"Clinicopathological Characteristics and Clinical Outcome in Egyptian Female Breast Cancer Patients With and Without BRCA1/2 Mutations","authors":"S. Abdelhamid, H. El-mesallamy, Hm AbdelAziz, A. Zekri","doi":"10.1177/0300891620914131","DOIUrl":"https://doi.org/10.1177/0300891620914131","url":null,"abstract":"Introduction: Germline mutations in BRCA1 and BRCA2 genes confer high risk of developing breast cancer. We sought to examine whether the clinicopathological characteristics and the clinical outcome differ in patients with and without BRCA mutations. Patients and Methods: A series of 103 Egyptian female patients were recruited from Breast Cancer Unit, Clinical Oncology Department, Ain Shams University, Egypt. The enrolled patients, unselected for age of onset or family history, were tested for BRCA1/2 mutations using HRM analysis and direct sequencing. The clinical and pathological features of the patients were retrospectively assessed and comparisons were made using Chi-square. Disease free survival (DFS) was estimated by Kaplan–Meier method and compared in the two groups with log-rank. Results: The overall rate of BRCA1/2 mutations was 44%. Novel deleterious mutations were detected and submitted to NCBI Clinvar database. Deleterious mutations were identified in 29 cases and unclassified variants in 32 cases, 15 of which had a co-occuring deleterious mutation. Patients with BRCA mutations tended to have early onset breast cancer compared to non-carriers (P=0.002), more often premenopausal (P=0.006), with a familial history of breast cancer as well as other cancers (P=0.005). BRCA-related breast cancers were more likely to have T3-T4 stage than wild type (41% versus 28%, P=0.02), positive lymph node involvement (78 versus 53%, P=0.007) and develop bilateral breast cancers (24% versus 9%, P =0.007). The incidence of ER negative and PR negative tumors was higher in BRCA carriers, but not statistically significant (P=0.17 and 0.15, respectively). No difference in HER-2/neu status was observed (P=0.25). Early age at onset, positive lymph node involvement, family history of any cancer were independent predictive factors for occurrence of BRCA1/2 mutations. The median follow-up time for the cohort was 5.53 years. Patients with BRCA mutations had poorer 5-year DFS compared to non-carriers (47.7% versus 67.4%, P=0.041); but Cox regression analysis failed to demonstrate a significant independent influence of BRCA mutation status on DFS. Conclusion: This study shows that BRCA-related breast cancers in the Egyptian population have distinctive clinical and tumor features as well as outcome. This data has important health implications for guiding cancer control policies.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"12 1","pages":"11 - 11"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81656439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891620914123
A. Semmar, S. El Majjaoui, H. El kacemi, T. Kebdani, N. Benjaafar
Objective: The aim of our study is to define the main factors contributing to the satisfaction of patients undergoing radiochemotherapy in outpatient setting. Materials and Methods: 100 Patients undergoing ambulatory concomitant radiochemotherapy in National Institute of Oncology at Rabat in Morocco were invited to complete the OUT-PATSAT35 questionnaire, evaluating perception of doctors, nurses and aspects of care organization, translated on Arabic language. The data were collected from different patients, over a period of three months. Statistical analysis was performed to determine which parameters had the greatest influence on overall satisfaction. Results: Overall satisfaction with the provided care was high with a mean satisfaction score of 3.19. Significant correlations were found between overall satisfaction and each of the following survey items: professional skills provided by doctors, behavior of doctors towards patients (patients support), behaviors of nurses towards patients, human qualities of nurses (politeness, respect, kindness and patience), care information provided by nurses, waiting time to get a medical consultation appointment, speed of execution of radiological examination and treatment and service organization. Linear regression analysis demonstrated that service organization, behavior of doctors and nurses towards patients, and care information provided by nurses were the strongest predictors for overall satisfaction, followed by waiting time to get a medical consultation appointment, speed of execution of radiological examination and treatment. Conclusion: Our study shows that the majority of our patients are satisfied with the level of our service, but the waiting time to get a medical consultation appointment, and speed of execution of radiological examination and treatment needs to be developed.
{"title":"Patient satisfaction in Ambulatory Radiochemotherapy: a study based on the Out-Patsat35 questionnaire","authors":"A. Semmar, S. El Majjaoui, H. El kacemi, T. Kebdani, N. Benjaafar","doi":"10.1177/0300891620914123","DOIUrl":"https://doi.org/10.1177/0300891620914123","url":null,"abstract":"Objective: The aim of our study is to define the main factors contributing to the satisfaction of patients undergoing radiochemotherapy in outpatient setting. Materials and Methods: 100 Patients undergoing ambulatory concomitant radiochemotherapy in National Institute of Oncology at Rabat in Morocco were invited to complete the OUT-PATSAT35 questionnaire, evaluating perception of doctors, nurses and aspects of care organization, translated on Arabic language. The data were collected from different patients, over a period of three months. Statistical analysis was performed to determine which parameters had the greatest influence on overall satisfaction. Results: Overall satisfaction with the provided care was high with a mean satisfaction score of 3.19. Significant correlations were found between overall satisfaction and each of the following survey items: professional skills provided by doctors, behavior of doctors towards patients (patients support), behaviors of nurses towards patients, human qualities of nurses (politeness, respect, kindness and patience), care information provided by nurses, waiting time to get a medical consultation appointment, speed of execution of radiological examination and treatment and service organization. Linear regression analysis demonstrated that service organization, behavior of doctors and nurses towards patients, and care information provided by nurses were the strongest predictors for overall satisfaction, followed by waiting time to get a medical consultation appointment, speed of execution of radiological examination and treatment. Conclusion: Our study shows that the majority of our patients are satisfied with the level of our service, but the waiting time to get a medical consultation appointment, and speed of execution of radiological examination and treatment needs to be developed.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"6 1","pages":"4 - 4"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75280763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Obesity is a global health problem, especially in the Arab region, the prevalence of obesity is increasing. High body mass index (BMI) is a risk factor for many diseases, including cancer. Noticeably, breast cancer (BC) cases in Saudi Arabia occur at a younger age than western countries and different life style behaviours such as maintaining healthy body weight and physical activity may play a role in this. In this study, we aimed to investigate the association between BMI and BC clinicopathological features. Methods: This retrospective study was conducted by reviewing the records of females diagnosed with non-metastatic BC over four years. The association between BMI and patients’ demographics, BC histological type, receptor status, differentiation grade, tumor size, involvement of axillary lymph node, and performed procedures was analysed. Result: We studied 315 patients with non-metastatic BC. The mean age at the time of diagnosis was 52.43 years ±11.63. The mean BMI was 30.21±5.77. The mean tumor size was 3.19 cm ± 3.52. We found that the mean age of diagnosis is significantly greater in obese women than other BMI groups with a P-value = 0.025. A significant relationship was observed between BMI classification and tumor size in obese female patients aged ⩾ 40 years with P-value=0.022 Conclusion: The relationship between BMI and BC is still not clear, in this study we found an association with age at diagnosis and tumor size in older patients, characteristics as histological types, receptor status, lymph node involvement, and grade were not statistically significant.
{"title":"The Association of Body Mass Index and Adverse Clinico-Pathological Characteristics of Non-Metastatic Breast Cancer Among Patients from Saudi Arabia","authors":"Bashayer Alghamdi, Reema Alghamdi, Raghad Khallaf, Konooz Faisal, Raghad Bishnaq, Atlal M. Abusanad","doi":"10.1177/0300891620914128","DOIUrl":"https://doi.org/10.1177/0300891620914128","url":null,"abstract":"Background: Obesity is a global health problem, especially in the Arab region, the prevalence of obesity is increasing. High body mass index (BMI) is a risk factor for many diseases, including cancer. Noticeably, breast cancer (BC) cases in Saudi Arabia occur at a younger age than western countries and different life style behaviours such as maintaining healthy body weight and physical activity may play a role in this. In this study, we aimed to investigate the association between BMI and BC clinicopathological features. Methods: This retrospective study was conducted by reviewing the records of females diagnosed with non-metastatic BC over four years. The association between BMI and patients’ demographics, BC histological type, receptor status, differentiation grade, tumor size, involvement of axillary lymph node, and performed procedures was analysed. Result: We studied 315 patients with non-metastatic BC. The mean age at the time of diagnosis was 52.43 years ±11.63. The mean BMI was 30.21±5.77. The mean tumor size was 3.19 cm ± 3.52. We found that the mean age of diagnosis is significantly greater in obese women than other BMI groups with a P-value = 0.025. A significant relationship was observed between BMI classification and tumor size in obese female patients aged ⩾ 40 years with P-value=0.022 Conclusion: The relationship between BMI and BC is still not clear, in this study we found an association with age at diagnosis and tumor size in older patients, characteristics as histological types, receptor status, lymph node involvement, and grade were not statistically significant.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"31 1","pages":"8 - 8"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74343538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1177/0300891619868301
P. Orsaria, A. Grasso, Rita Carino, E. Caredda, M. Sammarra, C. Altomare, C. Rabitti, G. Gullotta, G. Perrone, F. Pantano, O. Buonomo, V. Altomare
Background: Most cases of breast lesions of uncertain malignant potential (B3) undergo surgical intervention. We aimed to analyze the outcome of B3 lesion subtypes in a large series of screen-detected cases. Methods: We screened 2,986 core needle biopsies to classify B3 lesions. Positive predictive values (PPVs) for malignancy were calculated for a comprehensive risk characterization according to clinicopathologic and morphologic variables. Results: B3 lesions comprised 35% atypical ductal hyperplasia (PPV = 20%), 16.7% flat epithelial atypia (PPV = 12%), 22.7% lobular neoplasia (PPV = 16.2%), 9% papillary lesion (PPV = 18.5%), 8.6% phyllodes tumor (PPV = 3.8%), and 8% radial scars (PPV = 4.1%) based on histopathologic diagnosis. Upgrade rates were 15.9% for calcifications, 13.7% for mass lesions, and 16.7% for architectural deformities, with 8.3% of malignant lesions classified as ductal carcinoma in situ and 6.7% as invasive cancers (PPV = 15%). Conclusion: B3 lesions entail a heterogeneous risk of malignancy, and careful radiologic–pathologic correlation is required for optimal treatment.
{"title":"Heterogeneous risk profiles among B3 breast lesions of uncertain malignant potential","authors":"P. Orsaria, A. Grasso, Rita Carino, E. Caredda, M. Sammarra, C. Altomare, C. Rabitti, G. Gullotta, G. Perrone, F. Pantano, O. Buonomo, V. Altomare","doi":"10.1177/0300891619868301","DOIUrl":"https://doi.org/10.1177/0300891619868301","url":null,"abstract":"Background: Most cases of breast lesions of uncertain malignant potential (B3) undergo surgical intervention. We aimed to analyze the outcome of B3 lesion subtypes in a large series of screen-detected cases. Methods: We screened 2,986 core needle biopsies to classify B3 lesions. Positive predictive values (PPVs) for malignancy were calculated for a comprehensive risk characterization according to clinicopathologic and morphologic variables. Results: B3 lesions comprised 35% atypical ductal hyperplasia (PPV = 20%), 16.7% flat epithelial atypia (PPV = 12%), 22.7% lobular neoplasia (PPV = 16.2%), 9% papillary lesion (PPV = 18.5%), 8.6% phyllodes tumor (PPV = 3.8%), and 8% radial scars (PPV = 4.1%) based on histopathologic diagnosis. Upgrade rates were 15.9% for calcifications, 13.7% for mass lesions, and 16.7% for architectural deformities, with 8.3% of malignant lesions classified as ductal carcinoma in situ and 6.7% as invasive cancers (PPV = 15%). Conclusion: B3 lesions entail a heterogeneous risk of malignancy, and careful radiologic–pathologic correlation is required for optimal treatment.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"8 1","pages":"115 - 125"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79897831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：